Reaction
Pancreatic Failure reporting signals
As of the last recalculation, Pancreatic Failure appears in 1,687 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 324.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pancrelipase | 635 | 324.9 | 330.4 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 31 | 31.2 | 31.3 |
| Lanreotide Acetate | 15 | 23.8 | 23.9 |
| Dornase Alfa | 28 | 17.9 | 17.9 |
| Phytonadione | 11 | 16.1 | 16.1 |
| Insulin Degludec | 17 | 9.0 | 9.0 |
| Abacavir Sulfate | 7 | 8.9 | 8.9 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 6 | 8.6 | 8.6 |
| Prednisolone Acetate | 7 | 8.4 | 8.4 |
| Olmesartan Medoxomil | 24 | 8.3 | 8.3 |
| Ipilimumab | 26 | 7.5 | 7.5 |
| Oral Semaglutide | 42 | 7.2 | 7.2 |
| Nevirapine | 5 | 6.9 | 6.9 |
| Tobramycin | 13 | 6.7 | 6.7 |
| Nivolumab | 51 | 6.7 | 6.7 |
| Teduglutide | 7 | 6.4 | 6.4 |
| Ivacaftor | 4 | 6.2 | 6.2 |
| Pembrolizumab | 51 | 6.1 | 6.1 |
| Lumacaftor And Ivacaftor | 4 | 5.8 | 5.8 |
| Insulin Lispro | 52 | 4.8 | 4.8 |
| Nintedanib | 12 | 4.7 | 4.7 |
| Risankizumab-Rzaa | 29 | 4.4 | 4.4 |
| Erenumab-Aooe | 14 | 3.2 | 3.2 |
| Dulaglutide | 22 | 3.1 | 3.1 |